Clinical Trial

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Study acronym: DANBLOCK
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2018-12-16; most recent amendment 2025-06-05.
Status change: Recruiting → Active, Not Recruiting 2024-12-06
Status change: Not Yet Recruiting → Recruiting 2020-01-29
Trial Details
NCT Number NCT03778554
Lead Sponsor Bispebjerg Hospital
Collaborators: Amager Hospital, University Hospital Bispebjerg and Frederiksberg, Bornholm Hospital, Gentofte Hospital, Glostrup University Hospital, Copenhagen, Herlev Hospital, Hvidovre University Hospital, Nordsjaellands Hospital, Holbaek Hospital, Nykoebing Hospital, Naestved Hospital, Zealand University Hospital, Slagelse Hospital, Odense University Hospital, Svendborg Hospital, Sydvestjysk Sygehus, Hospital of Southern Jutland, Sygehus Lillebaelt (Vejle and Kolding), Aarhus University Hospital, Hospitalsenheden Midt, Hospitalsenheden Vest, Regionshospitalet Horsens, Silkeborg Sygehus, Aalborg University Hospital
Conditions Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction (nSTEMI), ST Elevation Myocardial Infarction
Enrollment 2,760 participants
Start Date 2018-12-17
Primary Completion 2025-04-01 (estimated)
Study Completion 2035-12-10 (estimated)
Updated on ClinicalTrials.gov 2025-06-10